Current Report Filing (8-k)
August 06 2019 - 2:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): August 6, 2019 (July 15, 2019)
Inspyr
Therapeutics, Inc.
(Exact
name of registrant as specified in Charter)
|
Delaware
|
|
0001421204
|
|
20-0438951
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employee
Identification No.)
|
31200
Via Colinas, Suite 200
Westlake
Village CA 91362
(Address
of Principal Executive Offices)
818-661-6302
(Issuer
Telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Resignation
of Christopher Lowe as Chief Executive Officer
On
July 15, 2019, Inspyr Therapeutics, Inc. (the “Company”) was informed by Christopher Lowe, that he is resigning as
chief executive officer, chief, financial officer, president, and as a member of the board of directors (“Board”)
of the Company. Mr. Lowe’s resignation did not result from any disagreement with the Company on any matter relating to its
operations, policies or practices.
Appointment
of Interim Chief Executive Officer and Board Member
On
July 26, 2019, the Company appointed Michael Cain to serve as the interim chief executive officer, chief financial officer, president,
and as a member of the Board. Mr. Cain will serve on an interim basis as principal executive and financial officer on an at-will
basis. The Company is not a party to any employment agreement or contract related to Mr. Cain’s employment and he will not
receive any compensation at this time. There are no family relationships between Mr. Cain and any of the directors or officers
of the Company, or any of its subsidiaries. There are no existing or currently proposed transactions to which the Company or any
of its subsidiaries is a party and in which Mr. Cain has a direct or indirect material interest.
Michael
Cain
, 35 has over 15 years of experience in technology and computer consulting fields. Mr. Cain serves as the President
and as a Board member of Level 4 Services, Inc, a private information technology company since 2013. In evaluating Mr. Cain’s
specific experience, qualifications, attributes and skills in connection with his appointment to our Board, we took into account
his management experience in other organizations and business development background.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed
on its behalf by the undersigned hereunto duly authorized.
|
|
Inspyr Therapeutics, Inc.
|
|
|
|
|
|
Dated:
August 6, 2019
|
By:
|
/s/
Michael Cain
|
|
|
|
Michael Cain
Chief Executive Officer
|
2